On the expected delisting of ordinary shares of Syros Pharmaceuticals, Inc. (SYRS)

The International Trading System Limited (ITS) informs of the forthcoming delisting of ordinary shares of Syros Pharmaceuticals, Inc. (ISIN US87184Q2066) from The NASDAQ Stock Market LLC (Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On February 28, 2025, Syros Pharmaceuticals, Inc. (the Company) submitted a report on Form 8-K to The United States Securities and Exchange Commission (SEC). According to the report, on February 28, 2025, the Company determined to take action to delist the Company’s common stock from Nasdaq. The Company intends to file a Form 25 with the SEC on or about March 10, 2025, removing the Company’s securities from listing on Nasdaq.

Information regarding possible actions to be taken by ITS

ITS will publish separate notices on the procedures undertaken by ITS outlining how trading in these qualified investments will be carried out.

In view of the upcoming delisting of the Company’s common stock from Nasdaq, ITS intends to limit short selling and to shift the opening of trading in respect of the Company’s ordinary shares in the Main Trading Mode to 19:30 Astana time on every trading day starting from March 04, 2025.

If Nasdaq suspends trading in the Company’s ordinary shares before the delisting, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. When the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.